key: cord-0895429-wydt1ykq authors: Saenz, Luis C.; Miranda, Antonio; Speranza, Ricardo; Texeira, Ricardo Alkmim; Rojel, Ulises; Enriquez, Andres; Figuereido, Marcio title: Recommendations for the organization of electrophysiology and cardiac pacing services during the COVID-19 pandemic: Latin American Heart Rhythm Society (LAHRS) in collaboration with: Colombian College Of Electrophysiology, Argentinian Society of Cardiac Electrophysiology (SADEC), Brazilian Society Of Cardiac Arrhythmias (SOBRAC), Mexican Society Of Cardiac Electrophysiology (SOMEEC) date: 2020-04-29 journal: J Interv Card Electrophysiol DOI: 10.1007/s10840-020-00747-5 sha: e92a907734de275a7838523d718b4b07eac7180f doc_id: 895429 cord_uid: wydt1ykq COVID-19 is a rapidly evolving public health emergency that has largely impacted the provision of healthcare services around the world. The challenge for electrophysiology teams is double; on one side preventing disease spread by limiting all nonessential face-to-face interactions, but at the same time ensuring continued care for patients who need it. These guidelines contain recommendations regarding triaging in order to define what procedures, device checks and clinic visits can be postponed during the pandemic. We also discuss best practices to protect patients and healthcare workers and provide guidance for the management of COVID-19 patients with arrhythmic conditions. The rapid expansion of the current COVID-19 pandemic and the sudden, unexpected demand for medical care to treat infected patients has overwhelmed the capacity of health care systems in many countries where the disease has spread [1, 2] . Strict social distancing measures have been applied and hospitals around the globe have had to implement drastic and quick changes to cope with the crisis. According to published statistics, a significant percentage of COVID-19 infections are acquired in hospitals [2] , with the potential risk of crosscontamination among health care workers, which limits even further the capacity to respond to the pandemic. For these reasons, it is imperative to reorganize outpatient and inhospital services in order to optimize the use of technical and human resources, but most importantly to protect patients, health care workers, and their families from the risk of transmission. The Latin American Heart Rhythm Society (LAHRS), in collaboration with the Argentinian, Brazilian, and Mexican Societies of Electrophysiology (SADEC, SOBRAC, SOMEC) and the Colombian College of Electrophysiology, has decided to contribute to this effort with the formulation of practical recommendations to guide rational reduction of faceto-face clinical interactions to the strictly and absolutely necessary. The recommendations outlined in this document are in accordance with guidelines issued by international organizations to prevent the spread of COVID-19 infection [3] [4] [5] [6] and have been adapted to the activities specific to our field. They will be in place while community-based measures are maintained by regulatory bodies at the international and local levels and could be modified in the short term depending on the behavior of the pandemic and the issuance of new global public health guidelines. In addition, we have proposed general recommendations for the antiarrhythmic management of patients with COVID-19 infection. In the absence of specific clinical studies guiding antiarrhythmic management in these patients, our recommendations are based on international consensus guidelines and are aimed to minimize unnecessary exposure risk while at the same time maintaining essential care for urgent arrhythmic conditions that, if untreated, could result in patient harm or clinical decompensation requiring hospital admission. The recommendations relative to remote consults and monitoring must conform to local regulations, which may vary between countries and institutions. 1. Minimize the risk of COVID-19 transmission to patients, health care workers, and their families by reducing unnecessary person-to-person exposure and contact with surfaces or areas contaminated with the virus 2. Ensure the continuous provision of electrophysiology clinical care by protecting our team members from illness or mandatory quarantines 3. Optimize the use of personal protection equipment (PPE), prioritizing its use by frontline health workers 4. Rationalize the use of hospital technical and human resources, so they can be focused in the management of COVID-19 patients Person-to-person spread of SARS-CoV2 (severe acute respiratory syndrome coronavirus 2), the virus responsible for COVID-19, is thought to occur primarily via respiratory droplets produced when the infected person coughs, sneezes, or talks. Infection can also occur if a person touches an infected surface and then touches his/her eyes, nose, or mouth. The relevance of airborne transmission is currently uncertain. 1. Health care workers providing care for suspect or confirmed COVID-19 patient should adhere to standard precautions and use a respirator or facemask, gown, gloves, and eye protection (goggles or face shield) [7] . 2. A respirator (N95 or higher-level respirator) should be used instead of a facemask for electrophysiology procedures requiring intubation or conscious sedation with high flow oxygen (considered aerosol generating procedures). 4 Follow-up of cardiac implantable electronic devices 1. We recommend a case-by-case triage of patients previously scheduled for in-clinic consult in order to determine if the visit can be postponed while social distancing measures are in place (Table 1 ). This decision should be based on analysis of the clinical history, data from last device interrogation, and information regarding clinical stability assessed by telephone contact. Telephone contact should include questions to identify suspected or confirmed COVID-19 cases (e.g., travel history, sick contacts, and respiratory symptoms). 2. We recommend postponing in-clinic follow-ups of patients with CIEDs that have been evaluated within the previous year if their clinical condition is stable and there are no device alerts. 3. In patients nearing battery depletion that cannot be followed remotely, the need for in-clinic assessment should be decided based on the battery estimated longevity measured at the last follow-up and pacing-dependence. 4. In patients with recently implanted devices, we recommend postponing in-clinic evaluation if their condition is stable and there were no findings during the implant warranting early follow-up. 5. Patients on remote monitoring should continue to be followed remotely. Patients with devices amenable to remote monitoring in which this function has not been activated, should be encouraged to switch to remote monitoring. 6. In patients with an implantable loop recorder (ILR) that cannot be followed remotely, we recommend postponing in-clinic evaluation if their condition is stable. 7. We recommend proper documentation of remote device follow-ups according to local regulations. We recommend postponing Holter or event monitors of any duration, unless there is a high suspicion index for arrhythmic syncope. This recommendation is based on the potential risk of exposure for patients and healthcare workers during placement and removal of a device that has been in contact with the patient for ≥ 24 h. Monitors can also be shipped by mail to the patients, who set up the device themselves, but this option is not available in most centers. 3. In recent years, smartphones and wearable devices have incorporated technology capable of monitoring heart rhythm (e.g., Kardia and Apple SmartWatch) [9] . These devices are able to generate single-lead ECG recordings that can be exported into a PDF and emailed to the physician's office. When this technology is available, its use should be encouraged, according to local regulations. The occurrence of cardiac arrhythmias has been reported as one of the most frequent manifestations in patients admitted with COVID-19 infection and they can be secondary to hypoxia or metabolic, neurohormonal, and inflammatory factors related to the infection [10] [11] [12] [13] . The clinical spectrum is broad and may include conduction disorders, AF/flutter, and malignant ventricular arrhythmias, which may represent exacerbation of chronic conditions or de novo arrhythmias with a potentially reversible mechanism. As expected, to date there have been no clinical studies to guide antiarrhythmic management in patients with COVID-19 infection and our recommendations are based on the experience from management of critically ill patients with other infectious diseases. It should be noted that antiarrhythmic drugs may be another component of a pharmacological regimen that often includes antivirals, antibiotics, and immunomodulators, with potential for pharmacological interactions and risk of pro-arrhythmia. We recommend coordination between the electrophysiology team and other hospital units in order to implement protocols of remote consultation when possible, especially in areas such as the intensive care unit or the emergency department. 2. We recommend proper documentation of remote inpatient consults according to local regulations. 3. In patients with supraventricular and ventricular arrhythmias, secondary causes should be investigated and treated: hypoxia, metabolic and electrolyte imbalances, proarrhythmic effect of drugs, or myocardial ischemia. 4. In patients with new-onset ventricular arrhythmias and troponin elevation, myocarditis should be ruled out as a causal factor. 5. In patients with AF/futter: a. Betablockers are recommended as first-line therapy. b. Use of amiodarone is reserved for patients with hemodynamic instability despite betablockers due to its potential interaction with other QTp r o l o n g i n g d r u g s ( h y d r o x y c h l o r o q u i n e , azythromicin, lopinavir/ritonavir) used to treat COVID-19 infection. c. In patients treated with amiodarone and especially with concomitant use of other QT-prolonging drugs (hydroxychloroquine, azythromicin, lopinavir/ritonavir), frequent electrolyte and QT monitoring is recommended to minimize the risk of pro-arrhythmia. d. Early anticoagulation with unfractionated heparin is recommended for prevention of embolic events, reducing the need for transoesophageal echocardiogram (TEE) if electrical cardioversion is required. e. In patients treated with antivirals or immunomodulators the use of oral anticoagulants should be avoided due to potential interaction. In patients with VT/VF without reversible causes: a. Betablockers and/or amiodarone are recommended as first-line agents. b. Careful use of amiodarone is recommended, with frequent electrolyte and QT monitoring to minimize the risk of pro-arrhythmia, especially in patients with concomitant use of other QT-prolonging drugs (hydroxychloroquine, azythromicin, lopinavir/ ritonavir). c. The use of amiodarone is contraindicated in patients with ventricular arrhythmias secondary to electrolyte imbalances and QT prolongation. These patients should be treated according to published guidelines. d. In patients with electrical storm not related to hypoxia, metabolic or electrolyte imbalances, or proarrhythmic effect drugs, management should include general anesthesia and betablockers in addition to amiodarone. In refractory cases, initiation of epidural anesthesia with bupivacaine could be considered. e. Patients with electrical storm refractory to the aforementioned measures should be evaluated in a case-bycase basis to decide possible escalation of therapies, including the use of ECMO. In patients with active COVID-19 infection who develop symptomatic or hemodynamically unstable bradyarrhythmias, insertion of a temporary pacemaker is recommended due to their potentially transient nature. 8. When feasible, suspected or confirmed COVID-19 cases requiring electrophysiology procedures should be -Preexcited AF or Wolf-Parkinson-White syndrome with syncope of suspected arrhythmic etiology scheduled at the end of the day as extensive disinfection/ cleaning would be required post-procedure. 9. Cardiopulmonary resuscitation (CPR) in COVID-19 patients with VF arrest involves a high risk of aerosolization and disease transmission. All participants should don full PPE for aerosol generating procedures (respirator, gown, gloves, and eye protection) before starting CPR in suspect or confirmed COVID-19 patients. 1. Electrical cardioversion should be reserved for refractory cases of AF/atrial flutter or SVT not responding to optimal medical therapy. Postponing elective electrical cardioversion is recommended in stable and asymptomatic patients. 2. Early anticoagulation is recommended in patients with AF/ atrial flutter to avoid the need for TEE, which is an aerosol generating procedure, if electrical cardioversion is indicated. 3. Performing CT instead of TEE could be considered to rule out left atrial appendage thrombus before electrical cardioversion in AF/atrial flutter patients with no optimal anticoagulation. Several drugs used to treat COVID-19 infection, including hydroxychloroquine, azythromicin and antivirals such as lopinavir/ritonavir, have the potential for QT interval prolongation and torsades de pointes [14] . A 12-lead ECG to measure the QTc interval is recommended at baseline and after initiation of any QTprolonging drug. 2. Patients with a baseline QTc > 500 ms and those with a QTc prolongation > 60 ms post exposure to medications are at increased risk for torsades de pointes and a riskbenefit analysis should be undertaken [15] . 3. In patients with abnormal QT prolongation, we recommend correction of electrolytes abnormalities (K + > 4 mEq/l, Mg 2+ > 2 mEq/l), discontinuation of unnecessary QT-prolonging drugs and continuous telemetry for monitoring of ventricular arrhythmias. If torsades de pointes is noted on telemetry, all QTc prolonging drugs should be discontinued. 4. The US Food and Drugs Administration (FDA) has approved the use of KardiaMobile 6 L (AliveCore) to monitor the QTc duration in COVID-19 patients receiving QTprolonging drugs [16] . This avoids exposure of ECG technicians to affected patients and unnecessary use of PPE. 13 Recommendations to minimize exposure in patients, health care workers, and their families Clinical Characteristics of Coronavirus Disease 2019 in China Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) COVID-19: towards controlling of a pandemic Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19) Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation: Moving Hearts Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease Coronaviruses and the cardiovascular system: acute and long-term implications Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID19 Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations the strictly necessary as the most effective and efficient measure to reduce the risk of COVID-19 spread. 2. We encourage all electrophysiology team members to adhere to basic preventive measures including frequent handwashing, social distancing, and self-isolation or quarantine when appropriate. 3. We recommend sharing the current recommendations with other hospital services through official channels. 4. Before any in-person clinical interactions such as outpatient clinic appointments, inpatient consults, or electrophysiology invasive procedures, we recommend checking if the patient is suspicious or has tested positive for COVID-19 infection in order to take additional safety precautions.